5-Methoxyharmalan
Pharmaceutical compound
From Wikipedia, the free encyclopedia
5-Methoxyharmalan, also known as 5-methoxy-1-methyl-4,9-dihydro-3H-β-carboline, is a serotonin receptor modulator of the β-carboline family.[1][2][3] It is a cyclized tryptamine analogue of 4-MeO-DMT and a positional isomer of 6-methoxyharmalan and harmaline (7-methoxyharmalan).[2][3]
- None
 | |
 | |
| Clinical data | |
|---|---|
| Other names | 5-MeO-harmalan; 5-OMe-harmalan; 5-Methoxy-1-methyl-4,9-dihydro-3H-β-carboline |
| Drug class | Serotonin receptor modulator |
| ATC code |
|
| Identifiers | |
| |
| PubChem CID | |
| ChemSpider | |
| ChEMBL | |
| Chemical and physical data | |
| Formula | C13H14N2O |
| Molar mass | 214.268 g·mol−1 |
| 3D model (JSmol) | |
| |
| |
Pharmacology
The drug shows high affinity for the serotonin 5-HT2A and 5-HT2C receptors (Ki = 86–137 nM and 69 nM, respectively).[2][3] It had higher affinity for these receptors than any other assessed β-carboline, with 1.7–4.6-fold, 57–58-fold, and >73–116-fold the affinity of harmine, harmaline, and tetrahydroharmine for the serotonin 5-HT2A receptor, respectively.[2][3] However, like harmaline and 6-methoxyharmalan, 5-methoxyharmalan showed no agonist or antagonist activity at the serotonin 5-HT2A receptor in terms of phosphatidylinositol (PI) hydrolysis in vitro at concentrations of up to 10,000 nM (and harmaline further showed no agonist activity in this assay at up to 20,000 nM).[2] It is unclear whether the serotonin 5-HT2A receptor is involved in the hallucinogenic or other psychoactive effects of β-carbolines.[2][3]
5-Methoxyharmalan showed no affinity for the melatonin receptors.[4] The 1-demethyl analogue of 5-methoxyharmalan shows high affinity for the imidazoline I2 receptor and the α2 receptor, whereas 5-methoxyharmalan itself was not assessed.[5]
History
5-Methoxyharmalan was first described in the scientific literature by 1993.[4]
See also
- Substituted β-carboline
- 6-Methoxyharmalan
- Harmaline (7-methoxyharmalan)